

19. Giraud E, Cloeckaert A, Kerboeuf D, Chaslus-Dancla E. Evidence of active efflux as the primary mechanism of resistance to ciprofloxacin in *Salmonella enterica* serovar *typhimurium*. *Antimicrob Agents Chemother* 2000; 44:1223–1228.
20. Bisognano C, Vaudaux P, Rohner P, Lew DP, Hooper DC. Induction of fibronectin-binding proteins and increased adhesion of quinolone-resistant *Staphylococcus aureus* by subinhibitory levels of ciprofloxacin. *Antimicrob Agents Chemother* 2000; 44:1428–1437.
21. Curtis CG, Lorrian V. Effects of low concentrations of antibiotics on bacterial ultrastructure, virulence, and susceptibility to immunodefenses: clinical significance. In: Lorrian V, ed. *Antibiotics in laboratory medicine, 4th edn*. Baltimore: Williams & Wilkins; 1996:397–452.
22. Odenholt I. Pharmacodynamic effects of subinhibitory antibiotic concentrations [review]. *Int J Antimicrob Agents* 2001; 17:1–8.

Eur J Nucl Med (2001) 28:781
 DOI 10.1007/s002590100521
 Published online: 20 April 2001
 © Springer-Verlag 2001

Reply

Dear Sir,

It is a pity that Britton et al. continue to misunderstand and misinterpret our work. Our research has never been centered around ^{99m}Tc-ciprofloxacin. We used it as a control agent for our own experiments with ^{99m}Tc-labelled cationic peptides for infection detection.

As a matter of fact, in our experiments we prepared ^{99m}Tc-ciprofloxacin according to the method published by Britton's group [1], and it was with this preparation that they obtained the most promising clinical results. The preparation method was once more confirmed by Solanki, who, on behalf of Britton, sent us the protocol for the preparation of ^{99m}Tc-ciprofloxacin. What would be more logical than to use this preparation, perform pre-clinical tests with it and report some of our pre-clinical results obtained with it? As pointed out, this was done only as a sideline in our own experiments, for which we needed a control agent.

We would be very interested to see the results obtained by Britton and his colleagues in respect of the pre-clinical testing, including the radiochemical data, of their clinically successful ^{99m}Tc-ciprofloxacin preparation. The best option would be to publish them in a peer-reviewed international scientific journal, as we did with our results [2, 3].

E.K.J. Pauwels, M.M. Welling

Department of Radiology,
 Division of Nuclear Medicine,
 Leiden University Medical Center,
 C4-Q, P.O. Box 9600,
 2300 RC Leiden, The Netherlands

A. Lupetti

Dipartimento di Patologia Sperimentale,
 Biotecnologie Mediche,
 Infettivologia ed Epidemiologia,
 Università degli Studi di Pisa,
 Pisa, Italy

P.H. Nibbering

Department of Infectious Diseases,
 Leiden University Medical Center,
 Leiden, The Netherlands

E.K.J. Pauwels (✉)

Department of Radiology,
 Division of Nuclear Medicine,
 Leiden University Medical Center,
 C4-Q, P.O. Box 9600,
 2300 RC Leiden, The Netherlands
 e-mail: e.k.j.pauwels@lumc.nl

References

1. Vinjamuri S, Hall AV, Solanki KK, Bomanji JB, Siraj Q, O'Shaughnessy EM, Das SS, Britton KE. Comparison of ^{99m}Tc-Infecton imaging with radiolabelled white-cell imaging in the evaluation of bacterial infection. *Lancet* 1996; 347:233–235.
2. Welling MM, Paulusma-Annema A, Balter HS, Pauwels EKJ, Nibbering PH. Technetium-99m labelled antimicrobial peptides discriminate between bacterial infections and sterile inflammations. *Eur J Nucl Med* 2000; 27:292–301.
3. Welling MM, Nibbering PH, Paulusma-Annema A, Hiemstra PS, Pauwels EKJ, Calame W. Imaging of bacterial infections with ^{99m}Tc-labelled human neutrophil peptide-1 [letter to the editor]. *J Nucl Med* 2000; 41:2099–2102.